- Home
- XGN vs ATOS Comparison
XGN vs ATOS Comparison
Compare XGN & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- ATOS
- Stock Information
- Founded
- XGN 2002
- ATOS 2009
- Country
- XGN United States
- ATOS United States
- Employees
- XGN N/A
- ATOS N/A
- Industry
- XGN Medical Specialities
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- ATOS Health Care
- Exchange
- XGN Nasdaq
- ATOS Nasdaq
- Market Cap
- XGN 138.3M
- ATOS 112.5M
- IPO Year
- XGN 2019
- ATOS 2012
- Fundamental
- Price
- XGN $7.00
- ATOS $0.88
- Analyst Decision
- XGN Strong Buy
- ATOS Strong Buy
- Analyst Count
- XGN 2
- ATOS 3
- Target Price
- XGN $7.50
- ATOS $6.17
- AVG Volume (30 Days)
- XGN 237.8K
- ATOS 1.5M
- Earning Date
- XGN 08-04-2025
- ATOS 08-11-2025
- Dividend Yield
- XGN N/A
- ATOS N/A
- EPS Growth
- XGN N/A
- ATOS N/A
- EPS
- XGN N/A
- ATOS N/A
- Revenue
- XGN $56,724,000.00
- ATOS N/A
- Revenue This Year
- XGN $19.39
- ATOS N/A
- Revenue Next Year
- XGN $13.27
- ATOS N/A
- P/E Ratio
- XGN N/A
- ATOS N/A
- Revenue Growth
- XGN 1.78
- ATOS N/A
- 52 Week Low
- XGN $1.71
- ATOS $0.55
- 52 Week High
- XGN $7.95
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- XGN 52.23
- ATOS 57.16
- Support Level
- XGN $6.62
- ATOS $0.77
- Resistance Level
- XGN $7.35
- ATOS $0.92
- Average True Range (ATR)
- XGN 0.48
- ATOS 0.04
- MACD
- XGN -0.10
- ATOS 0.00
- Stochastic Oscillator
- XGN 29.63
- ATOS 75.06
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.